Literature DB >> 34496

Methodology for demonstrating sustained efficacy of hypnotics: a comparative study of triazolam and flurazepam.

P R Sundaresan, W M Wardell, M Weintraub, L Lasagna.   

Abstract

To test for sustained hypnotic efficacy, triazolam (0.6 mg) or flurazepam (30 mg) was given to chronic insomniac patients for 7 consecutive nights in parallel, double-blind design. Triazolam at this dose was an effective hypnotic by all usual subjective measures and did not produce appreciable hangover. Flurazepam performed similarly. For either drug, comparison of the mean scores for the first 2 nights with that for the last 2 nights for any of the parameters did not reveal any significant difference. Thus, both triazolam and flurazepam showed sustained efficacy for 1 week at these doses. Some interesting theoretical and practical questions about the measurement of sustained efficacy of hypnotics in situations of repetitive dosing were addressed by the study. While a placebo control is desirable, the results obtained may be uninterpretable. An acute-care hospital setting may not be the ideal setting for doing such studies. There were indications from the study that the first-night results in a hypnotic clinical trial may be atypical.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 34496     DOI: 10.1002/cpt1979254391

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  Comparison of quazepam, flunitrazepam and placebo as single-dose hypnotics before surgery.

Authors:  E Wickstrøm; C Allgulander
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  The use of short- and long-acting hypnotics in clinical medicine.

Authors:  A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1981       Impact factor: 4.335

3.  Effects of triazolam (0.5 mg) on sleep, performance, memory, and arousal threshold.

Authors:  C L Spinweber; L C Johnson
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.